Seagen : FDA Grants Accelerated Approval To Tukysa Combination For Colorectal Cancer Treatment

(RTTNews) – Seagen Inc. (SGEN) said Thursday that the U.S. Food and Drug Administration has granted accelerated approval to Tukysa (tucatinib) in combination with trastuzumab for adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that ha

admin